All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: LP0162
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Results from a pooled safety analysis of three Phase 3 trials Phase 2 and Phase 2b trials demonstrate overall frequency of AEs with tralokinumab was comparable to placebo in the initial 16-week period in adults with moderate-to-severe atopic dermatitis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: LP0162
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Data demonstrating efficacy of Tralokinumab, a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and other inflammatory diseases, will be presented at the EADV Virtual 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab,Mometasone Furoate
Therapeutic Area: Dermatology Product Name: LP0162
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Results show maintained response with tralokinumab in ECZTRA 1, 2 and ECZTRA 3 over 52 weeks and 32 weeks, respectively. In ECZTRA 3, there was reduction in use of TCS in adult patients receiving tralokinumab plus TCS compared to placebo plus TCS
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: LP0162
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2020
Details:
Submission includes data from pivotal ECZTRA 1, 2 and ECZTRA 3 Phase 3 studies evaluating safety and efficacy of tralokinumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
Details:
The MAA is based on data from the pivotal ECZTRA 1, 2 and 3 Phase 3 studies evaluating the efficacy and safety of tralokinumab.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tralokinumab
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
Data include pivotal efficacy and safety clinical trials of tralokinumab monotherapy and tralokinumab with concomitant topical corticosteroid use in adult patients with moderate-to-severe atopic dermatitis.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
